In a pooled analysis of four NSCLC clinical trials, obese (body mass index [BMI] ≥ 30 kg/m2) and overweight individuals (BMI 25–29.9 kg/m2) with PD-L1-positive tumors treated with atezolizumab monotherapy had longer OS compared to normal weight (BMI 18.5–24.9 kg/m2) PD-L1-positive patients5. This evidence concerns the gene CD274 and non-small cell lung carcinoma.